Brian Wong
Chief Executive Officer chez RAPT THERAPEUTICS, INC.
Fortune : 4 M $ au 31/03/2024
Profil
Dr. Wong joined The Column Group in 2022 as a Venture Partner.
He is CEO of RAPT Therapeutics.
Prior to RAPT, he served as Senior Vice President, Research, and Head of Immuno-Oncology at Five Prime Therapeutics.
Prior to FivePrime, Dr. Wong served as Director in the Inflammation Disease Biology Area at Roche.
There, he led the discovery and supported the development of Roche’s autoimmune disease portfolio, consisting of more than 20 biologics and small-molecule programs from discovery to late-stage clinical development and through approval.
Prior to Roche, he held various leadership roles at Rigel Pharmaceuticals, where he identified and developed clinical candidates for allergic, autoimmune and respiratory disorders, including Tavalisse™.
Dr. Wong received his M.D.
from the Weill Cornell Medical College and his Ph.D.
in Immunology from Rockefeller University.
Board of Directors: Plexium
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RAPT THERAPEUTICS, INC.
1,42% | 28/03/2024 | 492 618 ( 1,42% ) | 4 M $ | 31/03/2024 |
Postes actifs de Brian Wong
| Sociétés | Poste | Début |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Chief Executive Officer | 01/08/2015 |
Plexium, Inc.
 Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Director/Board Member | 13/07/2022 |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Private Equity Investor | 01/04/2022 |
Anciens postes connus de Brian Wong
| Sociétés | Poste | Fin |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Corporate Officer/Principal | 30/08/2015 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Chief Tech/Sci/R&D Officer | 01/01/2009 |
| RIGEL PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Brian Wong
| Oberlin College | Undergraduate Degree |
| The Rockefeller University | Doctorate Degree |
| Weill Cornell Medical College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Plexium, Inc.
Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Health Technology |
